繁體
简体中文
繁體中文

傑龍 GERN 深 滬

已收盤 11-20 16:00:00 美东时间

0.8707

-0.042

-4.63%

华盛通華盛通
立即下載
  • 最 高0.925
  • 今 開0.89
  • 成交量 1383.33万股
  • 最 低 0.8615
  • 昨 收 0.913
  • 總市值 5.61亿
  • 52周最高 2.01
  • 市盈率 靜 --
  • 換手率 2.15%
  • 52周最低 0.84
  • 委 比 80.87%
  • 總股本 6.44亿
  • 歷史最高 7.79
  • 量 比 0.82
  • 振 幅 6.96%
  • 歷史最低 0.75
  • 每 手 1
  • 風險率 0.21%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors

    Conexeu Sciences Inc. announced the appointment of Daniel M. Bradbury as Chairman of the Board of Directors, effective December 1, 2026. Mr. Bradbury, with over 40 years of experience in the life sciences industry, succeeds Jeff Sharpe, who stepped down to make way for him. Bradbury previously served as CEO of Amylin Pharmaceuticals, which was acquired by Bristol-Myers Squibb for $7 billion, and has held leadership roles at multiple biotech compa...

    11-19 13:30

  • 杰龙收跌0.91%,成交额3401.02万美元

    11月19日,杰龙(GERN)收跌0.91%,报0.99美元,成交额3401.02万美元,市值6.38亿美元。 行情数据 • 开盘价:1美元 • 最高价:1....

    11-19 06:58

  • Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation granted stock options to purchase 150,000 shares of common stock to three newly hired employees, effective November 17, 2026. The options have an exercise price of $1.00 per share, a ten-year term, and vest over four years, with 12.5% vesting after six months of employment and the remaining shares vesting in equal installments over the next 42 months. The awards were granted under Nasdaq Listing Rule 5635(c)(4) and Geron’s 2018 ...

    11-18 21:05

  • 杰龙收跌2.24%,成交额1230.39万美元

    11月11日,杰龙(GERN)收跌2.24%,报0.97美元,成交额1230.39万美元,市值6.28亿美元。 行情数据 • 开盘价:0.99美元 • 最高价...

    11-11 06:58

  • 杰龙收涨0.68%,成交额567.75万美元

    11月10日,杰龙(GERN)收涨0.68%,报1美元,成交额567.75万美元,市值6.42亿美元。 行情数据 • 开盘价:0.99美元 • 最高价:1美元...

    11-10 06:59

  • 杰龙2026财年第2季度营收5748万美元,同比增长17.22%

    最新财报显示,杰龙2026财年第2季度实现: 营业收入:5748万美元 同比:增长17.22% 净利润:-1668万美元 同比:下降1.86% 每股收益:-0...

    11-07 04:00

  • 电话会总结 | Geron Corp(GERN)2026财年Q3业绩电话会核心要点

    <span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>&#8226; # Geron Corporation(GERN)2026财年第三季度业绩回顾摘要 ## 1. 财务业绩 **营业收入(Revenue):** - 第三季度净产品收入为6,010万美元,上年同期为4,720万美元。 - 同比增长27%,环比(较2026年第二季度)增长5%。 **净利润(Net Income):** - 第三季度净利润为140万美元,摊薄后每股收益为0.00美元。 - 上年同期为净亏损1,840万美元,实现扭亏为盈,成为公司转型为商业化阶段生物制药公司以来首次盈利季度。 **营业利润(Operating Income):** - 第三

    11-05 12:03

  • Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting

    Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology (ASH) Annua...

    11-04 22:02

  • Geron Q3 2026 Earnings Call Transcript

    Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more...

    11-04 21:52

  • 杰龙收涨3.88%,成交额1259.46万美元

    11月3日,杰龙(GERN)收涨3.88%,报0.93美元,成交额1259.46万美元,市值5.97亿美元。 行情数据 • 开盘价:0.9美元 • 最高价:0...

    11-03 06:59